Nerve growth factor-beta induces mast-cell marker expression during in vitro culture of human umbilical cord blood cells.

PubWeight™: 0.80‹?›

🔗 View Article (PMC 2327167)

Published in Immunology on March 01, 2000

Authors

P Welker1, J Grabbe, B Gibbs, T Zuberbier, B M Henz

Author Affiliations

1: Department of Dermatology, Charité, Humboldt-University, Berlin, Germany.

Articles cited by this

Mast cells. Physiol Rev (1997) 6.51

The trk proto-oncogene encodes a receptor for nerve growth factor. Cell (1991) 4.54

Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. J Clin Invest (1993) 3.57

Human beta-nerve growth factor gene sequence highly homologous to that of mouse. Nature (1983) 3.17

Enhanced expression of a glyceraldehyde-3-phosphate dehydrogenase gene in human lung cancers. Cancer Res (1987) 2.65

Cloning and characterization of complementary DNA for human tryptase. J Clin Invest (1989) 2.12

Mast cells synthesize, store, and release nerve growth factor. Proc Natl Acad Sci U S A (1994) 1.97

Effect of nerve growth factor on the release of inflammatory mediators by mature human basophils. Blood (1992) 1.56

High affinity human IgE receptor (Fc epsilon RI). Analysis of functional domains of the alpha-subunit with monoclonal antibodies. J Biol Chem (1991) 1.49

Induction of differentiation of human mast cells from bone marrow and peripheral blood mononuclear cells by recombinant human stem cell factor/kit-ligand in long-term culture. Blood (1992) 1.49

Mast cells increase in tissues of neonatal rats injected with the nerve growth factor. Brain Res (1977) 1.43

Monoclonal antibody YB5.B8 identifies the human c-kit protein product. Blood (1991) 1.40

Selective growth of human mast cells induced by Steel factor, IL-6, and prostaglandin E2 from cord blood mononuclear cells. J Immunol (1996) 1.38

IL-3-dependent murine mast cells undergo apoptosis on removal of IL-3. Prevention of apoptosis by c-kit ligand. J Immunol (1993) 1.35

Development of human mast cells from umbilical cord blood cells by recombinant human and murine c-kit ligand. Proc Natl Acad Sci U S A (1993) 1.30

Nerve growth factor promotes human hemopoietic colony growth and differentiation. Proc Natl Acad Sci U S A (1988) 1.28

Immunohistochemical identification of mast cells in formaldehyde-fixed tissue using monoclonal antibodies specific for tryptase. J Pathol (1990) 1.17

Role of nerve growth factor in cutaneous wound healing: accelerating effects in normal and healing-impaired diabetic mice. J Exp Med (1998) 1.17

Interaction between nerve growth factor and lysophosphatidylserine on rat peritoneal mast cells. FEBS Lett (1982) 1.16

Some characteristics of histamine secretion from rat peritoneal mast cells stimulated with nerve growth factor. J Physiol (1986) 1.15

Development of human mast cells in vitro. Proc Natl Acad Sci U S A (1989) 1.13

Nerve growth factor induces development of connective tissue-type mast cells in vitro from murine bone marrow cells. J Exp Med (1991) 1.13

Mast cells and their mediators in cutaneous wound healing--active participants or innocent bystanders? Exp Dermatol (1999) 1.13

The expanding role of nerve growth factor: from neurotrophic activity to immunologic diseases. Allergy (1997) 1.11

Role of the KIT protooncogene in normal and malignant human hematopoiesis. Proc Natl Acad Sci U S A (1992) 1.09

Human skin tryptase: purification, partial characterization and comparison with human lung tryptase. Biochim Biophys Acta (1988) 1.08

Identification and partial characterization of a unique marker for human basophils. J Immunol (1995) 1.04

Nerve growth factor production by lymphocytes. J Immunol (1994) 1.03

Quantitation of tryptase, chymase, Fc epsilon RI alpha, and Fc epsilon RI gamma mRNAs in human mast cells and basophils by competitive reverse transcription-polymerase chain reaction. J Immunol (1995) 1.03

Phenotypic evaluation of cultured human mast and basophilic cells and of normal human skin mast cells. Arch Dermatol Res (1994) 1.02

Human mast cells express functional TrkA and are a source of nerve growth factor. Eur J Immunol (1997) 1.00

Structure, chromosomal assignment, and deduced amino acid sequence of a human gene for mast cell chymase. J Biol Chem (1991) 1.00

Stem cell factor, a novel cutaneous growth factor for mast cells and melanocytes. Arch Dermatol Res (1994) 0.98

Effects of nerve growth factor on rat peritoneal mast cells. Survival promotion and immediate-early gene induction. J Biol Chem (1994) 0.97

Expression and function of nerve growth factor and nerve growth factor receptor on cultured keratinocytes. J Invest Dermatol (1994) 0.97

Nerve growth factor prevents apoptosis of rat peritoneal mast cells through the trk proto-oncogene receptor. Blood (1995) 0.96

The receptors for nerve growth factor and other neurotrophins. Annu Rev Biochem (1993) 0.96

Expression of functional trk protooncogene in human monocytes. Proc Natl Acad Sci U S A (1993) 0.95

Expression of functional TrkA receptor tyrosine kinase in the HMC-1 human mast cell line and in human mast cells. Blood (1997) 0.94

Comparative cytokine release from human monocytes, monocyte-derived immature mast cells, and a human mast cell line (HMC-1). J Invest Dermatol (1994) 0.94

Poor response of cultured mast cells derived from mi/mi mutant mice to nerve growth factor. Blood (1994) 0.94

Nerve growth factor induces the expression of certain cytokine genes and bcl-2 in mast cells. Potential role in survival promotion. J Biol Chem (1996) 0.92

The role of mast cell degranulation products in mast cell hyperplasia. I. Mechanism of action of nerve growth factor. J Immunol (1990) 0.92

Release of stem cell factor from a human keratinocyte line, HaCaT, is increased in differentiating versus proliferating cells. J Invest Dermatol (1996) 0.92

Mediation of NGF-stimulated extracellular matrix invasion by the human melanoma low-affinity p75 neurotrophin receptor: melanoma p75 functions independently of trkA. Mol Biol Cell (1993) 0.92

In vitro generation of mast cell-like cells from human peripheral mononuclear phagocytes. Int Arch Allergy Appl Immunol (1983) 0.90

Basophil priming by neurotrophic factors. Activation through the trk receptor. J Immunol (1996) 0.90

Development of human connective tissue mast cells from purified blood monocytes. Immunology (1984) 0.89

Detection of human papillomaviruses in paraffin-embedded condylomata acuminata--comparison of immunohistochemistry, in situ hybridization, and polymerase chain reaction. J Invest Dermatol (1991) 0.88

Local injection of nerve growth factor (NGF) triggers degranulation of mast cells in rat paw. Neurosci Lett (1997) 0.86

Stem cell factor-dependent human cord blood derived mast cells express alpha- and beta-tryptase, heparin and chondroitin sulphate. Immunology (1996) 0.86

Neurotrophin function in skin. J Investig Dermatol Symp Proc (1997) 0.84

Age-dependent phenotypic switching of mast cells in NGF-transgenic mice. Neuroreport (1995) 0.84

Nerve growth factor and mast cell distribution in the skin of patients with systemic sclerosis. Clin Exp Rheumatol (1993) 0.84

Human mast cells produce and differentially express both soluble and membrane-bound stem cell factor. Scand J Immunol (1999) 0.83

Murine granulocyte-macrophage and mast cell colony formation promoted by nerve growth factor. Int Arch Allergy Immunol (1993) 0.83

Effects of nerve growth factor (NGF) and other fibroblast-derived growth factors on immature human mast cells (HMC-1). Immunology (1998) 0.83

Expression of neurotrophin genes in human fibroblasts: differential regulation of the brain-derived neurotrophic factor gene. Int J Dev Neurosci (1994) 0.82

Effect of NGF antibodies on mast cell distribution, histamine and substance P levels in the knee joint of TNF-arthritic transgenic mice. Rheumatol Int (1995) 0.81

Quantitative effects of peripheral monocytes and nerve growth factor on CNS neural morphometric outgrowth parameters in vitro. Exp Neurol (1996) 0.80

Development of markers for human basophils and mast cells. J Allergy Clin Immunol (1994) 0.80

mRNA variants encoding multiple forms of the high-affinity IgE receptor alpha subunit in transformed and nontransformed mast cells. Int Arch Allergy Appl Immunol (1991) 0.78

Interleukin-4 and nerve growth factor can act as cofactors for interleukin-3-induced histamine production in human umbilical cord blood cells in serum-free culture. Br J Haematol (1992) 0.78

Induction of human leukaemic mast cell differentiation by fibroblast supernatants, but not by stem cell factor. Scand J Immunol (1998) 0.75

Articles by these authors

Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy (2008) 12.35

Role of nonallergic hypersensitivity reactions in children with chronic urticaria. Allergy (1998) 3.20

Practical guide to skin prick tests in allergy to aeroallergens. Allergy (2011) 2.51

Unmet clinical needs in chronic spontaneous urticaria. A GA²LEN task force report. Allergy (2010) 2.34

Synthesis, storage, and release of vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) by human mast cells: implications for the biological significance of VEGF206. Mol Biol Cell (1998) 2.24

Allergic Rhinitis and its Impact on Asthma (ARIA): achievements in 10 years and future needs. J Allergy Clin Immunol (2012) 2.17

Assessment of histamine-releasing activity of sera from patients with chronic urticaria showing positive autologous skin test on human basophils and mast cells. Clin Exp Allergy (2004) 2.13

Chronic rhinosinusitis in Europe--an underestimated disease. A GA²LEN study. Allergy (2011) 2.13

GA(2)LEN skin test study I: GA(2)LEN harmonization of skin prick testing: novel sensitization patterns for inhalant allergens in Europe. Allergy (2009) 1.72

A case-control study of the relation between plasma selenium and asthma in European populations: a GAL2EN project. Allergy (2008) 1.66

Night-time sedating H1 -antihistamine increases daytime somnolence but not treatment efficacy in chronic spontaneous urticaria: a randomized controlled trial. Br J Dermatol (2014) 1.60

Insulin allergy: clinical manifestations and management strategies. Allergy (2008) 1.56

How to assess disease activity in patients with chronic urticaria? Allergy (2008) 1.55

C3a and C5a stimulate chemotaxis of human mast cells. Blood (1997) 1.55

EAACI/GA2LEN/EDF guideline: definition, classification and diagnosis of urticaria. Allergy (2006) 1.55

Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report. Allergy (2006) 1.54

Mast cells. Int J Dermatol (1995) 1.52

GA(2)LEN skin test study II: clinical relevance of inhalant allergen sensitizations in Europe. Allergy (2009) 1.51

Effects of a pseudoallergen-free diet on chronic spontaneous urticaria: a prospective trial. Allergy (2009) 1.49

Allergen extract-induced interleukin-10 in human memory B cells inhibits immunoglobulin E production. Clin Exp Allergy (2009) 1.47

Food allergy and non-allergic food hypersensitivity in children and adolescents. Clin Exp Allergy (2004) 1.45

Viruses and bacteria in acute asthma exacerbations--a GA² LEN-DARE systematic review. Allergy (2010) 1.45

Is a single oral dose of ivermectin sufficient in crusted scabies? Int J Dermatol (2001) 1.44

HIV positivity, protease inhibitor exposure and subclinical atherosclerosis: a systematic review and meta-analysis of observational studies. Heart (2009) 1.42

Risk of first-generation H(1)-antihistamines: a GA(2)LEN position paper. Allergy (2010) 1.42

Expression of interleukin-8 detected by in situ hybridization correlates with worse prognosis in primary cutaneous melanoma. J Pathol (1999) 1.40

[Urticaria pigmentosa and mastocytosis]. Dtsch Med Wochenschr (1998) 1.38

EAACI/GA2LEN/EDF guideline: management of urticaria. Allergy (2006) 1.28

Standard skin prick testing and sensitization to inhalant allergens across Europe--a survey from the GALEN network. Allergy (2005) 1.25

Development and implementation of guidelines in allergic rhinitis – an ARIA-GA2LEN paper. Allergy (2010) 1.24

Allergic rhinitis management pocket reference 2008. Allergy (2008) 1.23

MeDALL (Mechanisms of the Development of ALLergy): an integrated approach from phenotypes to systems medicine. Allergy (2011) 1.22

GA2LEN (Global Allergy and Asthma European Network) addresses the allergy and asthma 'epidemic'. Allergy (2009) 1.22

Important research questions in allergy and related diseases: nonallergic rhinitis: a GA2LEN paper. Allergy (2008) 1.20

Undertreatment of rhinitis symptoms in Europe: findings from a cross-sectional questionnaire survey. Allergy (2007) 1.16

Mast cells and their mediators in cutaneous wound healing--active participants or innocent bystanders? Exp Dermatol (1999) 1.13

Acute urticaria: clinical aspects and therapeutic responsiveness. Acta Derm Venereol (1996) 1.10

Metastatic potential of human melanoma cells in nude mice--characterisation of phenotype, cytokine secretion and tumour-associated antigens. Br J Cancer (1996) 1.09

Up-dosing with bilastine results in improved effectiveness in cold contact urticaria. Allergy (2013) 1.09

Important research questions in allergy and related diseases: 3-chronic rhinosinusitis and nasal polyposis - a GALEN study. Allergy (2009) 1.08

Miliaria crystallina in an intensive care setting. Clin Exp Dermatol (2004) 1.08

The German version of the Chronic Urticaria Quality-of-Life Questionnaire: factor analysis, validation, and initial clinical findings. Allergy (2009) 1.07

Identification of activating c-kit mutations in adult-, but not in childhood-onset indolent mastocytosis: a possible explanation for divergent clinical behavior. J Invest Dermatol (1998) 1.06

Chronic urticaria: an internet survey of health behaviours, symptom patterns and treatment needs in European adult patients. Br J Dermatol (2008) 1.06

ARIA-suggested drugs for allergic rhinitis: what impact on quality of life? A GA2LEN review. Allergy (2008) 1.05

Membrane transport proteins associated with drug resistance expressed in human melanoma. Am J Pathol (1995) 1.04

Successful treatment of cholinergic urticaria with anti-immunoglobulin E therapy. Allergy (2008) 1.04

Keratin 17 gene expression during the murine hair cycle. J Invest Dermatol (1997) 1.03

GA2LEN skin test study III: minimum battery of test inhalent allergens needed in epidemiological studies in patients. Allergy (2009) 1.03

Topical calcitriol enhances normal hair regrowth but does not prevent chemotherapy-induced alopecia in mice. Cancer Res (1996) 1.02

Phenotypic evaluation of cultured human mast and basophilic cells and of normal human skin mast cells. Arch Dermatol Res (1994) 1.02

Upregulation of TNF-alpha and IL-3 expression in lesional and uninvolved skin in different types of urticaria. J Allergy Clin Immunol (1999) 1.01

Ragweed sensitization in Europe - GA(2)LEN study suggests increasing prevalence. Allergy (2009) 0.99

Efficacy of desloratadine in intermittent allergic rhinitis: a GA(2)LEN study. Allergy (2009) 0.99

Personalized pollen-related symptom-forecast information services for allergic rhinitis patients in Europe. Allergy (2013) 0.98

Recommendations for assessing patient-reported outcomes and health-related quality of life in clinical trials on allergy: a GA(2)LEN taskforce position paper. Allergy (2009) 0.98

Methodology for development of the Allergic Rhinitis and its Impact on Asthma guideline 2008 update. Allergy (2008) 0.97

Specific recommendations for PROs and HRQoL assessment in allergic rhinitis and/or asthma: a GA(2)LEN taskforce position paper. Allergy (2010) 0.97

Acquired cold urticaria: clinical picture and update on diagnosis and treatment. Clin Exp Dermatol (2007) 0.97

Detection of native human complement components C3 and C5 and their primary activation peptides C3a and C5a (anaphylatoxic peptides) by ELISAs with monoclonal antibodies. J Immunol Methods (1988) 0.97

Inhibition of cytokine secretion from human leukemic mast cells and basophils by H1- and H2-receptor antagonists. Exp Dermatol (2000) 0.97

Mast cells and vasculature in atopic dermatitis--potential stimulus of neoangiogenesis. Allergy (2005) 0.97

Impact of vaccinations and infectious diseases on the risk of melanoma--evaluation of an EORTC case-control study. Eur J Cancer (2003) 0.97

Expression and functional activity of the IL-8 receptor type CXCR1 and CXCR2 on human mast cells. J Immunol (1998) 0.96

Clinical improvement and immunological changes in atopic dermatitis patients undergoing subcutaneous immunotherapy with a house dust mite allergoid: a pilot study. Clin Exp Allergy (2007) 0.96

Severe chronic allergic (and related) diseases: a uniform approach--a MeDALL--GA2LEN--ARIA position paper. Int Arch Allergy Immunol (2012) 0.96

Eosinophilic nasal polyps are a rich source of eotaxin, eotaxin-2 and eotaxin-3. Rhinology (2006) 0.95

Identification of chemotactic lipoxygenase products of arachidonate metabolism in psoriatic skin. J Invest Dermatol (1984) 0.95

The impact of GINA suggested drugs for the treatment of asthma on Health-Related Quality of Life: a GA(2)LEN review. Allergy (2008) 0.95

How to design and evaluate randomized controlled trials in immunotherapy for allergic rhinitis: an ARIA-GA(2) LEN statement. Allergy (2011) 0.95

Molecular regulation of human IgE synthesis. J Mol Med (Berl) (1997) 0.95

The relation between paracetamol use and asthma: a GA2LEN European case-control study. Eur Respir J (2008) 0.94

Human skin mast cells rapidly release preformed and newly generated TNF-alpha and IL-8 following stimulation with anti-IgE and other secretagogues. Exp Dermatol (2001) 0.94

Mastocytosis: recent advances in defining the disease. Br J Dermatol (2001) 0.94

Differential expression of angiotensin receptors in human cutaneous wound healing. Br J Dermatol (2005) 0.94

Quantitative detection of soluble adhesion molecules in sera of melanoma patients correlates with clinical stage. Dermatology (1996) 0.93

Biological and chemical characterization of eosinophil chemotactic factors from human leukocytes. Agents Actions Suppl (1983) 0.93

Prevention and control of childhood asthma and allergy in the EU from the public health point of view: Polish Presidency of the European Union. Allergy (2012) 0.93

Infections and melanoma risk: results of a multicentre EORTC case-control study. European Organization for Research and Treatment of Cancer. Melanoma Res (1999) 0.93

Chemotactic leukotrienes in psoriasis. Lancet (1982) 0.92

A combination of wheat flour, ethanol and food additives inducing FDEIA. Allergy (2002) 0.92

Hepatitis C virus infection rate in volunteer blood donors from the Western Cape--comparison of screening tests and PCR. S Afr Med J (1997) 0.92

Release of stem cell factor from a human keratinocyte line, HaCaT, is increased in differentiating versus proliferating cells. J Invest Dermatol (1996) 0.92

Bifunctional thrombin inhibitors based on the sequence of hirudin45-65. J Biol Chem (1990) 0.91

Production of interleukin-6 by human mast cells and basophilic cells. J Invest Dermatol (1996) 0.91

Novel unconventional therapeutic approaches to atopic eczema. Dermatology (2000) 0.91

Evaluation of systemic provocation tests in patients with suspected allergic and pseudoallergic drug reactions. Acta Derm Venereol (1999) 0.91

Successful treatment of solar urticaria with anti-immunoglobulin E therapy. Allergy (2008) 0.91

Candidate gene acting as a suppressor of the RH locus in most cases of Rh-deficiency. Nat Genet (1996) 0.91

Prior immunisation of patients with malignant melanoma with vaccinia or BCG is associated with better survival. An European Organization for Research and Treatment of Cancer cohort study on 542 patients. Eur J Cancer (2005) 0.91

Retinoic acid inhibits CD40 + interleukin-4-mediated IgE production in vitro. Blood (1998) 0.90

Erythema elevatum diutinum--evidence for disease-dependent leucocyte alterations and response to dapsone. Br J Dermatol (2000) 0.90